Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients
Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Feb 13, 2009
Trial Information
Current as of June 10, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Group T(n=30): patient without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor
- • Group A (n=30): patient with central adiposity, insulin resistance and hepatic steatosis (histology).
- • Group B (n=30): patient with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).
- Exclusion Criteria:
- • viral or autoimmune hepatitis
- • hematochromatosis
- • alcohol consumption (\> 20 g/24h women, \>30 g/24h men)
- • type 1 diabetes
- • inflammation or infection before procedure
- • abnormal hemostasis or coagulation- pregnancy
About University Hospital, Strasbourg, France
The University Hospital of Strasbourg, France, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the institution collaborates with a diverse range of healthcare professionals and research teams to explore cutting-edge therapies and treatment modalities. With state-of-the-art facilities and a multidisciplinary approach, the University Hospital of Strasbourg plays a pivotal role in translating scientific discoveries into effective clinical applications, contributing significantly to the advancement of medical knowledge and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Strasbourg, , France
Strasbourg, , France
Patients applied
Trial Officials
Michel DOFFOEL, MD
Principal Investigator
Hôpitaux Universitaires de Strasbourg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials